BiomaterialsBioprintingProduct Launch

BIOLAMINA partners with CELLINK for the development of biolaminin bioink products

New products will improve the structure and biochemical features of bioprinted constructs

Swedish 3D bioprinter manufacturer CELLINK is launching a brand new bioink containing BIOLAMININ, that will enable scientists to combine the unique properties of the laminin protein with culturing cells in a 3D-environment. This approach will advance the 3D bioprinting technology since the biological effect of the laminin protein will improve the structure and biochemical features, creating a microenvironment more authentic to the in vivo setting.

“We are stoked to be working together with one of the leading companies in the field of laminins as it will ensure our customers and partners will continue to get the highest quality products and reagents for their research. As a leading bioprinting technology provider, it’s essential to continue innovating and offering bioink products that create added value for our users. Our product development is always customer demand based and it’s a pleasure seeing this collaboration bringing new products to fruition”, says Erik Gatenholm, CEO of Cellink.


BIOLAMINA, also originating in Sweden, develops and manufactures laminin protein-based reagents, BIOLAMININS. Laminins are a key regulator of cell behavior and essential for maintaining tissue functions. The impact of BIOLAMININ matrices on the advances in cell-based research and for the development of reliable and robust processes for cell therapy applications have been published in many high-impact journals.

The two innovative companies, each with unique technologies, are thus uniting to create powerful tools for researches and companies developing the treatments of tomorrow. During recent years, 3D bioprinting has emerged as a powerful cell culture technology but has also been hampered by the lack of a biologically relevant Bioink.

“We are excited to announce this collaboration with Cellink and to get additional user applications for our outstanding products,” says Kristian Tryggvason, CEO of BIOLAMINA. “This collaboration is in line with our vision to provide the research community with tools to enable new cell assays, to revolutionize cell culture.”


Related Articles

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*